Spyre Therapeutics Quarterly Income Statement
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
85.69+5.79 (+7.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Spyre Therapeutics revenue and earnings
Spyre Therapeutics reported a net loss of $36.2 million, compared with a loss of $36.7 million a year earlier.
Summary generated from market data by MetaCap's automated system. Methodology
Spyre Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | -100.00% | -100.00% | -100.00% | -100.00% |
| Operating Expenses | 41.64M | 45.64M | 57.17M | 56.89M | 41.94M | 53.57M | 61.25M | 55.39M | 44.15M | 47.77M | 45.91M | 18.34M |
| Research & Development | 65.50M | 60.41M | 44.64M | 45.25M | 40.15M | 41.62M | 50.48M | 44.74M | 32.64M | 34.93M | 33.68M | 24.66M |
| Operating Income | -41.64M | -45.64M | -57.17M | -56.89M | -41.94M | -53.57M | -61.25M | -55.39M | -44.15M | -47.77M | -45.91M | -18.34M |
| Other Income (Expense) | 5.44M | -23.36M | -5.36M | 45.70M | 5.22M | 8.78M | 4.96M | -13.62M | 5.31M | 3.95M | -17.27M | -21.77M |
| Pretax Income | -36.20M | -69.00M | -62.53M | -11.18M | -36.72M | -44.79M | -56.30M | -69.01M | -38.84M | -43.83M | -63.18M | -40.10M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -15.00K | 1.00K | 18.00K | 0 | 32.00K | 0 | 3.00K |
| Net Income | -36.20M | -69.00M | -62.53M | -11.18M | -36.72M | -44.77M | -56.30M | -69.03M | -38.84M | -43.86M | -63.18M | -40.11M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | — | — | — | 1.06 | 0.59 | 0.72 | -22.35 | 0.86 |
| EPS (Diluted) | — | -0.74 | — | — | — | — | — | 1.06 | 0.59 | 0.72 | -22.35 | 0.86 |
| Shares Outstanding (Basic) | — | — | — | — | — | — | — | 50.89M | 45.32M | 36.51M | — | 4.29M |
| Shares Outstanding (Diluted) | — | — | — | — | — | — | — | 50.89M | 45.32M | 36.51M | — | 4.29M |
| EBITDA | — | — | — | — | — | — | -61.25M | -55.39M | -44.15M | -47.77M | -45.91M | -18.34M |
This table shows 12 quarterly periods of Spyre Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SYRE's reporting calendar. What is a income statement?